Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Arranon Generic Name & Formulations
Legal Class
Rx
General Description
Nelarabine 250mg/50mL; soln for IV infusion.
Pharmacological Class
Nucleoside analogue.
How Supplied
Single-use vials—6
Manufacturer
Arranon Indications
Indications
T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that is unresponsive or has relapsed after ≥2 chemotherapy regimens.
Arranon Dosage and Administration
Adult
Give by IV infusion over 2hrs. 1500mg/m2 on days 1, 3, and 5; repeat every 21 days. In clinical trials, treatment was generally continued until there was evidence of disease progression, patient experienced unacceptable toxicity, patient became a candidate for bone marrow transplant, or patient no longer continued to benefit from treatment. See full labeling.
Children
Give by IV infusion over 1hr. 650mg/m2 daily for 5 consecutive days; repeat every 21 days. In clinical trials, treatment was generally continued until there was evidence of disease progression, patient experienced unacceptable toxicity, patient became a candidate for bone marrow transplant, or patient no longer continued to benefit from treatment. See full labeling.
Arranon Contraindications
Not Applicable
Arranon Boxed Warnings
Boxed Warning
Neurologic adverse reactions.
Arranon Warnings/Precautions
Warnings/Precautions
Monitor closely for neurotoxicity; discontinue if ≥Grade 2 occurs. Prior or concurrent intrathecal chemotherapy or craniospinal irradiation (increased risk of neurotoxicity). May delay dosing if other toxicities occur (eg, hematologic toxicity). Monitor CBCs, platelet counts regularly, and for signs of infection. Moderate-to-severe renal or severe hepatic impairment; monitor. Ensure adequate hydration. Consider allopurinol for patients at risk for hyperuricemia. Elderly. Embryo-fetal toxicity. Use effective contraception during therapy and for 3 months (males) after last dose. Pregnancy; verify status prior to initiation. Nursing mothers: not recommended.
Arranon Pharmacokinetics
See Literature
Arranon Interactions
Interactions
Avoid live vaccines in immunocompromised. Concomitant adenosine deaminase inhibitors (eg, pentostatin): not recommended.
Arranon Adverse Reactions
Adverse Reactions
Anemia, thrombocytopenia, neutropenia, nausea, vomiting, diarrhea, constipation, fatigue, pyrexia, cough, dyspnea, somnolence, dizziness, peripheral neuropathy, hypoesthesia, headache, paresthesia; tumor lysis syndrome (monitor).
Arranon Clinical Trials
See Literature
Arranon Note
Not Applicable
Arranon Patient Counseling
See Literature
